nodes	percent_of_prediction	percent_of_DWPC	metapath
Haloperidol—CBR1—Doxorubicin—ovarian cancer	0.193	0.378	CbGbCtD
Haloperidol—ABCB1—ovarian cancer	0.185	1	CbGaD
Haloperidol—CYP3A7—Paclitaxel—ovarian cancer	0.03	0.0587	CbGbCtD
Haloperidol—CYP3A7-CYP3A51P—Paclitaxel—ovarian cancer	0.03	0.0587	CbGbCtD
Haloperidol—ABCB1—Topotecan—ovarian cancer	0.0296	0.0579	CbGbCtD
Haloperidol—CYP3A5—Paclitaxel—ovarian cancer	0.0225	0.044	CbGbCtD
Haloperidol—CYP3A7—Docetaxel—ovarian cancer	0.0217	0.0424	CbGbCtD
Haloperidol—CYP3A7-CYP3A51P—Docetaxel—ovarian cancer	0.0217	0.0424	CbGbCtD
Haloperidol—ABCB1—Vinorelbine—ovarian cancer	0.0208	0.0408	CbGbCtD
Haloperidol—CYP2D6—Vinorelbine—ovarian cancer	0.0196	0.0384	CbGbCtD
Haloperidol—CYP3A4—Topotecan—ovarian cancer	0.0177	0.0347	CbGbCtD
Haloperidol—CYP3A5—Docetaxel—ovarian cancer	0.0163	0.0318	CbGbCtD
Haloperidol—CYP2C9—Paclitaxel—ovarian cancer	0.0151	0.0295	CbGbCtD
Haloperidol—ABCB1—Paclitaxel—ovarian cancer	0.0146	0.0287	CbGbCtD
Haloperidol—CYP3A4—Vinorelbine—ovarian cancer	0.0125	0.0244	CbGbCtD
Haloperidol—ABCB1—Docetaxel—ovarian cancer	0.0106	0.0207	CbGbCtD
Haloperidol—CYP3A4—Paclitaxel—ovarian cancer	0.00878	0.0172	CbGbCtD
Haloperidol—ABCB1—Doxorubicin—ovarian cancer	0.00789	0.0154	CbGbCtD
Haloperidol—CYP2D6—Doxorubicin—ovarian cancer	0.00744	0.0146	CbGbCtD
Haloperidol—CYP3A4—Docetaxel—ovarian cancer	0.00635	0.0124	CbGbCtD
Haloperidol—H1F0—oviduct—ovarian cancer	0.00508	0.0587	CbGeAlD
Haloperidol—CYP3A4—Doxorubicin—ovarian cancer	0.00473	0.00925	CbGbCtD
Haloperidol—EBP—uterine cervix—ovarian cancer	0.00338	0.0391	CbGeAlD
Haloperidol—CBR1—Vincristine—Vinorelbine—ovarian cancer	0.00329	1	CbGdCrCtD
Haloperidol—HTR2A—vein—ovarian cancer	0.00318	0.0367	CbGeAlD
Haloperidol—EBP—uterus—ovarian cancer	0.00282	0.0326	CbGeAlD
Haloperidol—EBP—female reproductive system—ovarian cancer	0.00253	0.0293	CbGeAlD
Haloperidol—CBR1—myometrium—ovarian cancer	0.00198	0.0229	CbGeAlD
Haloperidol—H1F0—myometrium—ovarian cancer	0.00162	0.0188	CbGeAlD
Haloperidol—H1F0—embryo—ovarian cancer	0.00156	0.0181	CbGeAlD
Haloperidol—CBR1—uterine cervix—ovarian cancer	0.00154	0.0178	CbGeAlD
Haloperidol—DRD4—testis—ovarian cancer	0.0015	0.0173	CbGeAlD
Haloperidol—CBR1—decidua—ovarian cancer	0.00147	0.017	CbGeAlD
Haloperidol—CBR1—endometrium—ovarian cancer	0.0014	0.0161	CbGeAlD
Haloperidol—CBR1—gonad—ovarian cancer	0.00129	0.015	CbGeAlD
Haloperidol—CBR1—uterus—ovarian cancer	0.00129	0.0149	CbGeAlD
Haloperidol—H1F0—uterine cervix—ovarian cancer	0.00126	0.0146	CbGeAlD
Haloperidol—H1F0—decidua—ovarian cancer	0.0012	0.0139	CbGeAlD
Haloperidol—SIGMAR1—myometrium—ovarian cancer	0.00117	0.0136	CbGeAlD
Haloperidol—HTR2B—myometrium—ovarian cancer	0.00117	0.0135	CbGeAlD
Haloperidol—CBR1—female reproductive system—ovarian cancer	0.00116	0.0134	CbGeAlD
Haloperidol—H1F0—endometrium—ovarian cancer	0.00114	0.0132	CbGeAlD
Haloperidol—CBR1—bone marrow—ovarian cancer	0.00109	0.0126	CbGeAlD
Haloperidol—H1F0—gonad—ovarian cancer	0.00106	0.0123	CbGeAlD
Haloperidol—H1F0—uterus—ovarian cancer	0.00105	0.0122	CbGeAlD
Haloperidol—CBR1—female gonad—ovarian cancer	0.00105	0.0122	CbGeAlD
Haloperidol—CBR1—vagina—ovarian cancer	0.00105	0.0121	CbGeAlD
Haloperidol—H1F0—female reproductive system—ovarian cancer	0.000947	0.0109	CbGeAlD
Haloperidol—KCNH2—myometrium—ovarian cancer	0.000934	0.0108	CbGeAlD
Haloperidol—CBR1—testis—ovarian cancer	0.000933	0.0108	CbGeAlD
Haloperidol—SIGMAR1—uterine cervix—ovarian cancer	0.000913	0.0106	CbGeAlD
Haloperidol—HTR2B—uterine cervix—ovarian cancer	0.000911	0.0105	CbGeAlD
Haloperidol—H1F0—bone marrow—ovarian cancer	0.000894	0.0103	CbGeAlD
Haloperidol—SIGMAR1—decidua—ovarian cancer	0.00087	0.0101	CbGeAlD
Haloperidol—HTR2B—decidua—ovarian cancer	0.000868	0.01	CbGeAlD
Haloperidol—H1F0—female gonad—ovarian cancer	0.000862	0.00996	CbGeAlD
Haloperidol—H1F0—vagina—ovarian cancer	0.000856	0.0099	CbGeAlD
Haloperidol—SIGMAR1—endometrium—ovarian cancer	0.000826	0.00954	CbGeAlD
Haloperidol—HTR2B—endometrium—ovarian cancer	0.000824	0.00952	CbGeAlD
Haloperidol—H1F0—testis—ovarian cancer	0.000764	0.00883	CbGeAlD
Haloperidol—SIGMAR1—uterus—ovarian cancer	0.000761	0.00879	CbGeAlD
Haloperidol—HTR2B—uterus—ovarian cancer	0.000759	0.00877	CbGeAlD
Haloperidol—HTR1B—female reproductive system—ovarian cancer	0.000758	0.00876	CbGeAlD
Haloperidol—HRH1—myometrium—ovarian cancer	0.000748	0.00865	CbGeAlD
Haloperidol—HTR1D—female reproductive system—ovarian cancer	0.000734	0.00848	CbGeAlD
Haloperidol—KCNH2—uterine cervix—ovarian cancer	0.000726	0.0084	CbGeAlD
Haloperidol—HTR2B—female reproductive system—ovarian cancer	0.000682	0.00789	CbGeAlD
Haloperidol—CBR1—lymph node—ovarian cancer	0.000676	0.00781	CbGeAlD
Haloperidol—KCNH2—endometrium—ovarian cancer	0.000657	0.0076	CbGeAlD
Haloperidol—SIGMAR1—bone marrow—ovarian cancer	0.000646	0.00746	CbGeAlD
Haloperidol—SIGMAR1—female gonad—ovarian cancer	0.000622	0.00719	CbGeAlD
Haloperidol—CYP1A1—epithelium—ovarian cancer	0.000619	0.00715	CbGeAlD
Haloperidol—SIGMAR1—vagina—ovarian cancer	0.000619	0.00715	CbGeAlD
Haloperidol—HTR2B—vagina—ovarian cancer	0.000617	0.00713	CbGeAlD
Haloperidol—CYP1A1—uterine cervix—ovarian cancer	0.000614	0.00709	CbGeAlD
Haloperidol—KCNH2—uterus—ovarian cancer	0.000605	0.007	CbGeAlD
Haloperidol—HTR2A—embryo—ovarian cancer	0.000601	0.00695	CbGeAlD
Haloperidol—CYP3A5—uterine cervix—ovarian cancer	0.0006	0.00693	CbGeAlD
Haloperidol—HRH1—epithelium—ovarian cancer	0.000587	0.00679	CbGeAlD
Haloperidol—HRH1—uterine cervix—ovarian cancer	0.000582	0.00673	CbGeAlD
Haloperidol—HRH1—decidua—ovarian cancer	0.000555	0.00641	CbGeAlD
Haloperidol—H1F0—lymph node—ovarian cancer	0.000554	0.0064	CbGeAlD
Haloperidol—SIGMAR1—testis—ovarian cancer	0.000552	0.00638	CbGeAlD
Haloperidol—KCNH2—female reproductive system—ovarian cancer	0.000544	0.00629	CbGeAlD
Haloperidol—HRH1—endometrium—ovarian cancer	0.000527	0.00609	CbGeAlD
Haloperidol—CYP2C19—vagina—ovarian cancer	0.000516	0.00597	CbGeAlD
Haloperidol—KCNH2—bone marrow—ovarian cancer	0.000514	0.00594	CbGeAlD
Haloperidol—CYP1A1—uterus—ovarian cancer	0.000511	0.00591	CbGeAlD
Haloperidol—KCNH2—female gonad—ovarian cancer	0.000495	0.00573	CbGeAlD
Haloperidol—KCNH2—vagina—ovarian cancer	0.000492	0.00569	CbGeAlD
Haloperidol—HTR2A—epithelium—ovarian cancer	0.000491	0.00567	CbGeAlD
Haloperidol—CYP1A1—female reproductive system—ovarian cancer	0.00046	0.00531	CbGeAlD
Haloperidol—DRD2—testis—ovarian cancer	0.000446	0.00515	CbGeAlD
Haloperidol—CYP2C9—female reproductive system—ovarian cancer	0.000442	0.00511	CbGeAlD
Haloperidol—KCNH2—testis—ovarian cancer	0.000439	0.00508	CbGeAlD
Haloperidol—HRH1—female reproductive system—ovarian cancer	0.000436	0.00504	CbGeAlD
Haloperidol—CYP1A1—female gonad—ovarian cancer	0.000418	0.00484	CbGeAlD
Haloperidol—CYP1A1—vagina—ovarian cancer	0.000416	0.00481	CbGeAlD
Haloperidol—ABCB1—myometrium—ovarian cancer	0.00041	0.00473	CbGeAlD
Haloperidol—CYP3A5—female gonad—ovarian cancer	0.000409	0.00473	CbGeAlD
Haloperidol—HTR2A—gonad—ovarian cancer	0.000408	0.00472	CbGeAlD
Haloperidol—CYP3A5—vagina—ovarian cancer	0.000407	0.0047	CbGeAlD
Haloperidol—SIGMAR1—lymph node—ovarian cancer	0.0004	0.00462	CbGeAlD
Haloperidol—HTR2B—lymph node—ovarian cancer	0.000399	0.00461	CbGeAlD
Haloperidol—HRH1—female gonad—ovarian cancer	0.000397	0.00459	CbGeAlD
Haloperidol—HRH1—vagina—ovarian cancer	0.000395	0.00456	CbGeAlD
Haloperidol—ABCB1—embryo—ovarian cancer	0.000394	0.00455	CbGeAlD
Haloperidol—HTR2A—female reproductive system—ovarian cancer	0.000364	0.00421	CbGeAlD
Haloperidol—HRH1—testis—ovarian cancer	0.000352	0.00407	CbGeAlD
Haloperidol—CYP3A4—female reproductive system—ovarian cancer	0.000337	0.0039	CbGeAlD
Haloperidol—CYP2D6—female reproductive system—ovarian cancer	0.000332	0.00384	CbGeAlD
Haloperidol—HTR2A—vagina—ovarian cancer	0.00033	0.00381	CbGeAlD
Haloperidol—ABCB1—epithelium—ovarian cancer	0.000321	0.00372	CbGeAlD
Haloperidol—ABCB1—uterine cervix—ovarian cancer	0.000319	0.00368	CbGeAlD
Haloperidol—KCNH2—lymph node—ovarian cancer	0.000318	0.00368	CbGeAlD
Haloperidol—ABCB1—decidua—ovarian cancer	0.000304	0.00351	CbGeAlD
Haloperidol—CYP2D6—female gonad—ovarian cancer	0.000302	0.00349	CbGeAlD
Haloperidol—HTR2A—testis—ovarian cancer	0.000294	0.0034	CbGeAlD
Haloperidol—ABCB1—endometrium—ovarian cancer	0.000288	0.00333	CbGeAlD
Haloperidol—CYP1A1—lymph node—ovarian cancer	0.000269	0.00311	CbGeAlD
Haloperidol—CYP2D6—testis—ovarian cancer	0.000268	0.0031	CbGeAlD
Haloperidol—ABCB1—gonad—ovarian cancer	0.000267	0.00309	CbGeAlD
Haloperidol—ABCB1—uterus—ovarian cancer	0.000266	0.00307	CbGeAlD
Haloperidol—HRH1—lymph node—ovarian cancer	0.000255	0.00295	CbGeAlD
Haloperidol—Body temperature increased—Vinorelbine—ovarian cancer	0.000246	0.00157	CcSEcCtD
Haloperidol—Connective tissue disorder—Docetaxel—ovarian cancer	0.000246	0.00157	CcSEcCtD
Haloperidol—Urethral disorder—Docetaxel—ovarian cancer	0.000245	0.00157	CcSEcCtD
Haloperidol—Hyponatraemia—Epirubicin—ovarian cancer	0.000245	0.00156	CcSEcCtD
Haloperidol—Diarrhoea—Melphalan—ovarian cancer	0.000244	0.00156	CcSEcCtD
Haloperidol—Nausea—Chlorambucil—ovarian cancer	0.000243	0.00155	CcSEcCtD
Haloperidol—Vision blurred—Paclitaxel—ovarian cancer	0.000242	0.00155	CcSEcCtD
Haloperidol—Visual impairment—Docetaxel—ovarian cancer	0.000241	0.00154	CcSEcCtD
Haloperidol—Dizziness—Topotecan—ovarian cancer	0.000241	0.00154	CcSEcCtD
Haloperidol—Tremor—Paclitaxel—ovarian cancer	0.000241	0.00154	CcSEcCtD
Haloperidol—Dermatitis exfoliative—Doxorubicin—ovarian cancer	0.000239	0.00153	CcSEcCtD
Haloperidol—ABCB1—female reproductive system—ovarian cancer	0.000239	0.00276	CbGeAlD
Haloperidol—Anaemia—Paclitaxel—ovarian cancer	0.000237	0.00152	CcSEcCtD
Haloperidol—Agitation—Paclitaxel—ovarian cancer	0.000236	0.00151	CcSEcCtD
Haloperidol—Face oedema—Epirubicin—ovarian cancer	0.000235	0.0015	CcSEcCtD
Haloperidol—Eye disorder—Docetaxel—ovarian cancer	0.000234	0.00149	CcSEcCtD
Haloperidol—Cardiac disorder—Docetaxel—ovarian cancer	0.000232	0.00148	CcSEcCtD
Haloperidol—Cardiac arrest—Epirubicin—ovarian cancer	0.000232	0.00148	CcSEcCtD
Haloperidol—Vomiting—Topotecan—ovarian cancer	0.000232	0.00148	CcSEcCtD
Haloperidol—Hypoglycaemia—Doxorubicin—ovarian cancer	0.000231	0.00148	CcSEcCtD
Haloperidol—Vertigo—Paclitaxel—ovarian cancer	0.000231	0.00147	CcSEcCtD
Haloperidol—Lethargy—Doxorubicin—ovarian cancer	0.00023	0.00147	CcSEcCtD
Haloperidol—Leukopenia—Paclitaxel—ovarian cancer	0.00023	0.00147	CcSEcCtD
Haloperidol—Rash—Topotecan—ovarian cancer	0.00023	0.00147	CcSEcCtD
Haloperidol—Hypersensitivity—Vinorelbine—ovarian cancer	0.00023	0.00147	CcSEcCtD
Haloperidol—Dermatitis—Topotecan—ovarian cancer	0.00023	0.00147	CcSEcCtD
Haloperidol—Headache—Topotecan—ovarian cancer	0.000228	0.00146	CcSEcCtD
Haloperidol—Angiopathy—Docetaxel—ovarian cancer	0.000227	0.00145	CcSEcCtD
Haloperidol—Vomiting—Melphalan—ovarian cancer	0.000227	0.00145	CcSEcCtD
Haloperidol—Hyponatraemia—Doxorubicin—ovarian cancer	0.000227	0.00145	CcSEcCtD
Haloperidol—Immune system disorder—Docetaxel—ovarian cancer	0.000226	0.00144	CcSEcCtD
Haloperidol—ABCB1—bone marrow—ovarian cancer	0.000225	0.00261	CbGeAlD
Haloperidol—Mediastinal disorder—Docetaxel—ovarian cancer	0.000225	0.00144	CcSEcCtD
Haloperidol—Liver function test abnormal—Epirubicin—ovarian cancer	0.000225	0.00144	CcSEcCtD
Haloperidol—Rash—Melphalan—ovarian cancer	0.000225	0.00144	CcSEcCtD
Haloperidol—Dermatitis—Melphalan—ovarian cancer	0.000225	0.00144	CcSEcCtD
Haloperidol—Orthostatic hypotension—Epirubicin—ovarian cancer	0.000223	0.00142	CcSEcCtD
Haloperidol—Convulsion—Paclitaxel—ovarian cancer	0.000223	0.00142	CcSEcCtD
Haloperidol—Hypertension—Paclitaxel—ovarian cancer	0.000222	0.00142	CcSEcCtD
Haloperidol—Alopecia—Docetaxel—ovarian cancer	0.000221	0.00141	CcSEcCtD
Haloperidol—Pruritus—Vinorelbine—ovarian cancer	0.00022	0.00141	CcSEcCtD
Haloperidol—Breast disorder—Epirubicin—ovarian cancer	0.00022	0.00141	CcSEcCtD
Haloperidol—Mental disorder—Docetaxel—ovarian cancer	0.000219	0.0014	CcSEcCtD
Haloperidol—Anxiety—Paclitaxel—ovarian cancer	0.000218	0.00139	CcSEcCtD
Haloperidol—Face oedema—Doxorubicin—ovarian cancer	0.000218	0.00139	CcSEcCtD
Haloperidol—Malnutrition—Docetaxel—ovarian cancer	0.000218	0.00139	CcSEcCtD
Haloperidol—ABCB1—female gonad—ovarian cancer	0.000217	0.00251	CbGeAlD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.000217	0.00139	CcSEcCtD
Haloperidol—Nausea—Topotecan—ovarian cancer	0.000216	0.00138	CcSEcCtD
Haloperidol—ABCB1—vagina—ovarian cancer	0.000216	0.0025	CbGeAlD
Haloperidol—Cardiac arrest—Doxorubicin—ovarian cancer	0.000215	0.00137	CcSEcCtD
Haloperidol—Dry mouth—Paclitaxel—ovarian cancer	0.000214	0.00137	CcSEcCtD
Haloperidol—Diarrhoea—Vinorelbine—ovarian cancer	0.000213	0.00136	CcSEcCtD
Haloperidol—Nausea—Melphalan—ovarian cancer	0.000212	0.00135	CcSEcCtD
Haloperidol—Confusional state—Paclitaxel—ovarian cancer	0.000211	0.00135	CcSEcCtD
Haloperidol—Dysphagia—Epirubicin—ovarian cancer	0.000211	0.00135	CcSEcCtD
Haloperidol—Oedema—Paclitaxel—ovarian cancer	0.00021	0.00134	CcSEcCtD
Haloperidol—Anaphylactic shock—Paclitaxel—ovarian cancer	0.00021	0.00134	CcSEcCtD
Haloperidol—Muscle spasms—Docetaxel—ovarian cancer	0.000209	0.00134	CcSEcCtD
Haloperidol—Liver function test abnormal—Doxorubicin—ovarian cancer	0.000208	0.00133	CcSEcCtD
Haloperidol—Dizziness—Vinorelbine—ovarian cancer	0.000206	0.00132	CcSEcCtD
Haloperidol—Orthostatic hypotension—Doxorubicin—ovarian cancer	0.000206	0.00132	CcSEcCtD
Haloperidol—Nervous system disorder—Paclitaxel—ovarian cancer	0.000206	0.00131	CcSEcCtD
Haloperidol—Thrombocytopenia—Paclitaxel—ovarian cancer	0.000205	0.00131	CcSEcCtD
Haloperidol—Tachycardia—Paclitaxel—ovarian cancer	0.000205	0.00131	CcSEcCtD
Haloperidol—Breast disorder—Doxorubicin—ovarian cancer	0.000204	0.0013	CcSEcCtD
Haloperidol—Skin disorder—Paclitaxel—ovarian cancer	0.000204	0.0013	CcSEcCtD
Haloperidol—Hyperhidrosis—Paclitaxel—ovarian cancer	0.000203	0.00129	CcSEcCtD
Haloperidol—Anaemia—Docetaxel—ovarian cancer	0.000201	0.00129	CcSEcCtD
Haloperidol—Pancytopenia—Epirubicin—ovarian cancer	0.0002	0.00128	CcSEcCtD
Haloperidol—Anorexia—Paclitaxel—ovarian cancer	0.0002	0.00128	CcSEcCtD
Haloperidol—Vomiting—Vinorelbine—ovarian cancer	0.000198	0.00127	CcSEcCtD
Haloperidol—Neutropenia—Epirubicin—ovarian cancer	0.000197	0.00126	CcSEcCtD
Haloperidol—Rash—Vinorelbine—ovarian cancer	0.000197	0.00126	CcSEcCtD
Haloperidol—Dermatitis—Vinorelbine—ovarian cancer	0.000196	0.00125	CcSEcCtD
Haloperidol—Hypotension—Paclitaxel—ovarian cancer	0.000196	0.00125	CcSEcCtD
Haloperidol—Headache—Vinorelbine—ovarian cancer	0.000195	0.00125	CcSEcCtD
Haloperidol—Dysphagia—Doxorubicin—ovarian cancer	0.000195	0.00125	CcSEcCtD
Haloperidol—Leukopenia—Docetaxel—ovarian cancer	0.000195	0.00124	CcSEcCtD
Haloperidol—ABCB1—testis—ovarian cancer	0.000193	0.00223	CbGeAlD
Haloperidol—Photosensitivity reaction—Epirubicin—ovarian cancer	0.000192	0.00123	CcSEcCtD
Haloperidol—Weight increased—Epirubicin—ovarian cancer	0.000192	0.00123	CcSEcCtD
Haloperidol—Weight decreased—Epirubicin—ovarian cancer	0.000191	0.00122	CcSEcCtD
Haloperidol—Hyperglycaemia—Epirubicin—ovarian cancer	0.00019	0.00121	CcSEcCtD
Haloperidol—Insomnia—Paclitaxel—ovarian cancer	0.00019	0.00121	CcSEcCtD
Haloperidol—Convulsion—Docetaxel—ovarian cancer	0.000189	0.00121	CcSEcCtD
Haloperidol—Hypertension—Docetaxel—ovarian cancer	0.000188	0.0012	CcSEcCtD
Haloperidol—Drowsiness—Epirubicin—ovarian cancer	0.000188	0.0012	CcSEcCtD
Haloperidol—Dyspnoea—Paclitaxel—ovarian cancer	0.000187	0.00119	CcSEcCtD
Haloperidol—Somnolence—Paclitaxel—ovarian cancer	0.000186	0.00119	CcSEcCtD
Haloperidol—Pancytopenia—Doxorubicin—ovarian cancer	0.000185	0.00118	CcSEcCtD
Haloperidol—Nausea—Vinorelbine—ovarian cancer	0.000185	0.00118	CcSEcCtD
Haloperidol—Dyspepsia—Paclitaxel—ovarian cancer	0.000185	0.00118	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.000184	0.00118	CcSEcCtD
Haloperidol—Jaundice—Epirubicin—ovarian cancer	0.000183	0.00117	CcSEcCtD
Haloperidol—Neutropenia—Doxorubicin—ovarian cancer	0.000182	0.00116	CcSEcCtD
Haloperidol—Decreased appetite—Paclitaxel—ovarian cancer	0.000182	0.00116	CcSEcCtD
Haloperidol—Dry mouth—Docetaxel—ovarian cancer	0.000181	0.00116	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000181	0.00116	CcSEcCtD
Haloperidol—Constipation—Paclitaxel—ovarian cancer	0.000179	0.00115	CcSEcCtD
Haloperidol—Confusional state—Docetaxel—ovarian cancer	0.000179	0.00114	CcSEcCtD
Haloperidol—Photosensitivity reaction—Doxorubicin—ovarian cancer	0.000178	0.00114	CcSEcCtD
Haloperidol—Hepatobiliary disease—Epirubicin—ovarian cancer	0.000178	0.00114	CcSEcCtD
Haloperidol—Oedema—Docetaxel—ovarian cancer	0.000178	0.00114	CcSEcCtD
Haloperidol—Anaphylactic shock—Docetaxel—ovarian cancer	0.000178	0.00114	CcSEcCtD
Haloperidol—Weight increased—Doxorubicin—ovarian cancer	0.000177	0.00113	CcSEcCtD
Haloperidol—Weight decreased—Doxorubicin—ovarian cancer	0.000176	0.00113	CcSEcCtD
Haloperidol—Hyperglycaemia—Doxorubicin—ovarian cancer	0.000176	0.00112	CcSEcCtD
Haloperidol—Agranulocytosis—Epirubicin—ovarian cancer	0.000175	0.00112	CcSEcCtD
Haloperidol—Nervous system disorder—Docetaxel—ovarian cancer	0.000174	0.00111	CcSEcCtD
Haloperidol—Thrombocytopenia—Docetaxel—ovarian cancer	0.000174	0.00111	CcSEcCtD
Haloperidol—Drowsiness—Doxorubicin—ovarian cancer	0.000174	0.00111	CcSEcCtD
Haloperidol—Tachycardia—Docetaxel—ovarian cancer	0.000173	0.00111	CcSEcCtD
Haloperidol—Feeling abnormal—Paclitaxel—ovarian cancer	0.000173	0.0011	CcSEcCtD
Haloperidol—Skin disorder—Docetaxel—ovarian cancer	0.000173	0.0011	CcSEcCtD
Haloperidol—Jaundice—Doxorubicin—ovarian cancer	0.000169	0.00108	CcSEcCtD
Haloperidol—Anorexia—Docetaxel—ovarian cancer	0.000169	0.00108	CcSEcCtD
Haloperidol—Hepatitis—Epirubicin—ovarian cancer	0.000169	0.00108	CcSEcCtD
Haloperidol—Urinary tract disorder—Epirubicin—ovarian cancer	0.000167	0.00106	CcSEcCtD
Haloperidol—Urticaria—Paclitaxel—ovarian cancer	0.000167	0.00106	CcSEcCtD
Haloperidol—Hypotension—Docetaxel—ovarian cancer	0.000166	0.00106	CcSEcCtD
Haloperidol—Connective tissue disorder—Epirubicin—ovarian cancer	0.000166	0.00106	CcSEcCtD
Haloperidol—Body temperature increased—Paclitaxel—ovarian cancer	0.000166	0.00106	CcSEcCtD
Haloperidol—Urethral disorder—Epirubicin—ovarian cancer	0.000165	0.00106	CcSEcCtD
Haloperidol—Hepatobiliary disease—Doxorubicin—ovarian cancer	0.000164	0.00105	CcSEcCtD
Haloperidol—Visual impairment—Epirubicin—ovarian cancer	0.000163	0.00104	CcSEcCtD
Haloperidol—Agranulocytosis—Doxorubicin—ovarian cancer	0.000162	0.00104	CcSEcCtD
Haloperidol—Insomnia—Docetaxel—ovarian cancer	0.000161	0.00103	CcSEcCtD
Haloperidol—Dyspnoea—Docetaxel—ovarian cancer	0.000158	0.00101	CcSEcCtD
Haloperidol—Somnolence—Docetaxel—ovarian cancer	0.000158	0.00101	CcSEcCtD
Haloperidol—Eye disorder—Epirubicin—ovarian cancer	0.000158	0.00101	CcSEcCtD
Haloperidol—Cardiac disorder—Epirubicin—ovarian cancer	0.000157	0.001	CcSEcCtD
Haloperidol—Dyspepsia—Docetaxel—ovarian cancer	0.000156	0.000999	CcSEcCtD
Haloperidol—Hepatitis—Doxorubicin—ovarian cancer	0.000156	0.000997	CcSEcCtD
Haloperidol—Decreased appetite—Docetaxel—ovarian cancer	0.000154	0.000987	CcSEcCtD
Haloperidol—Hypersensitivity—Paclitaxel—ovarian cancer	0.000154	0.000987	CcSEcCtD
Haloperidol—Urinary tract disorder—Doxorubicin—ovarian cancer	0.000154	0.000985	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000153	0.00098	CcSEcCtD
Haloperidol—Connective tissue disorder—Doxorubicin—ovarian cancer	0.000153	0.00098	CcSEcCtD
Haloperidol—Angiopathy—Epirubicin—ovarian cancer	0.000153	0.000978	CcSEcCtD
Haloperidol—Urethral disorder—Doxorubicin—ovarian cancer	0.000153	0.000977	CcSEcCtD
Haloperidol—Immune system disorder—Epirubicin—ovarian cancer	0.000152	0.000973	CcSEcCtD
Haloperidol—Mediastinal disorder—Epirubicin—ovarian cancer	0.000152	0.000971	CcSEcCtD
Haloperidol—Constipation—Docetaxel—ovarian cancer	0.000152	0.000971	CcSEcCtD
Haloperidol—Visual impairment—Doxorubicin—ovarian cancer	0.00015	0.000961	CcSEcCtD
Haloperidol—Alopecia—Epirubicin—ovarian cancer	0.000149	0.000952	CcSEcCtD
Haloperidol—Pruritus—Paclitaxel—ovarian cancer	0.000148	0.000947	CcSEcCtD
Haloperidol—Mental disorder—Epirubicin—ovarian cancer	0.000148	0.000944	CcSEcCtD
Haloperidol—Malnutrition—Epirubicin—ovarian cancer	0.000147	0.000938	CcSEcCtD
Haloperidol—Feeling abnormal—Docetaxel—ovarian cancer	0.000146	0.000935	CcSEcCtD
Haloperidol—Eye disorder—Doxorubicin—ovarian cancer	0.000146	0.000932	CcSEcCtD
Haloperidol—Cardiac disorder—Doxorubicin—ovarian cancer	0.000145	0.000925	CcSEcCtD
Haloperidol—Diarrhoea—Paclitaxel—ovarian cancer	0.000143	0.000916	CcSEcCtD
Haloperidol—Angiopathy—Doxorubicin—ovarian cancer	0.000142	0.000905	CcSEcCtD
Haloperidol—Muscle spasms—Epirubicin—ovarian cancer	0.000141	0.000902	CcSEcCtD
Haloperidol—Immune system disorder—Doxorubicin—ovarian cancer	0.000141	0.000901	CcSEcCtD
Haloperidol—Mediastinal disorder—Doxorubicin—ovarian cancer	0.000141	0.000899	CcSEcCtD
Haloperidol—Body temperature increased—Docetaxel—ovarian cancer	0.00014	0.000897	CcSEcCtD
Haloperidol—ABCB1—lymph node—ovarian cancer	0.00014	0.00161	CbGeAlD
Haloperidol—Dizziness—Paclitaxel—ovarian cancer	0.000139	0.000886	CcSEcCtD
Haloperidol—Vision blurred—Epirubicin—ovarian cancer	0.000138	0.000884	CcSEcCtD
Haloperidol—Alopecia—Doxorubicin—ovarian cancer	0.000138	0.000881	CcSEcCtD
Haloperidol—Mental disorder—Doxorubicin—ovarian cancer	0.000137	0.000874	CcSEcCtD
Haloperidol—Malnutrition—Doxorubicin—ovarian cancer	0.000136	0.000868	CcSEcCtD
Haloperidol—Anaemia—Epirubicin—ovarian cancer	0.000136	0.000867	CcSEcCtD
Haloperidol—Agitation—Epirubicin—ovarian cancer	0.000135	0.000862	CcSEcCtD
Haloperidol—Vomiting—Paclitaxel—ovarian cancer	0.000133	0.000851	CcSEcCtD
Haloperidol—Rash—Paclitaxel—ovarian cancer	0.000132	0.000844	CcSEcCtD
Haloperidol—Dermatitis—Paclitaxel—ovarian cancer	0.000132	0.000844	CcSEcCtD
Haloperidol—Vertigo—Epirubicin—ovarian cancer	0.000132	0.000843	CcSEcCtD
Haloperidol—Leukopenia—Epirubicin—ovarian cancer	0.000131	0.00084	CcSEcCtD
Haloperidol—Headache—Paclitaxel—ovarian cancer	0.000131	0.000839	CcSEcCtD
Haloperidol—Hypersensitivity—Docetaxel—ovarian cancer	0.000131	0.000836	CcSEcCtD
Haloperidol—Muscle spasms—Doxorubicin—ovarian cancer	0.000131	0.000834	CcSEcCtD
Haloperidol—Vision blurred—Doxorubicin—ovarian cancer	0.000128	0.000818	CcSEcCtD
Haloperidol—Convulsion—Epirubicin—ovarian cancer	0.000127	0.000813	CcSEcCtD
Haloperidol—Hypertension—Epirubicin—ovarian cancer	0.000127	0.00081	CcSEcCtD
Haloperidol—Pruritus—Docetaxel—ovarian cancer	0.000126	0.000803	CcSEcCtD
Haloperidol—Anaemia—Doxorubicin—ovarian cancer	0.000126	0.000802	CcSEcCtD
Haloperidol—Agitation—Doxorubicin—ovarian cancer	0.000125	0.000798	CcSEcCtD
Haloperidol—Anxiety—Epirubicin—ovarian cancer	0.000125	0.000796	CcSEcCtD
Haloperidol—Nausea—Paclitaxel—ovarian cancer	0.000125	0.000795	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.000124	0.000793	CcSEcCtD
Haloperidol—Dry mouth—Epirubicin—ovarian cancer	0.000122	0.000781	CcSEcCtD
Haloperidol—Vertigo—Doxorubicin—ovarian cancer	0.000122	0.00078	CcSEcCtD
Haloperidol—Leukopenia—Doxorubicin—ovarian cancer	0.000122	0.000777	CcSEcCtD
Haloperidol—Diarrhoea—Docetaxel—ovarian cancer	0.000122	0.000777	CcSEcCtD
Haloperidol—Confusional state—Epirubicin—ovarian cancer	0.000121	0.000772	CcSEcCtD
Haloperidol—Oedema—Epirubicin—ovarian cancer	0.00012	0.000766	CcSEcCtD
Haloperidol—Anaphylactic shock—Epirubicin—ovarian cancer	0.00012	0.000766	CcSEcCtD
Haloperidol—Convulsion—Doxorubicin—ovarian cancer	0.000118	0.000752	CcSEcCtD
Haloperidol—Nervous system disorder—Epirubicin—ovarian cancer	0.000118	0.000751	CcSEcCtD
Haloperidol—Dizziness—Docetaxel—ovarian cancer	0.000117	0.000751	CcSEcCtD
Haloperidol—Thrombocytopenia—Epirubicin—ovarian cancer	0.000117	0.00075	CcSEcCtD
Haloperidol—Hypertension—Doxorubicin—ovarian cancer	0.000117	0.000749	CcSEcCtD
Haloperidol—Tachycardia—Epirubicin—ovarian cancer	0.000117	0.000747	CcSEcCtD
Haloperidol—Skin disorder—Epirubicin—ovarian cancer	0.000116	0.000744	CcSEcCtD
Haloperidol—Hyperhidrosis—Epirubicin—ovarian cancer	0.000116	0.00074	CcSEcCtD
Haloperidol—Anxiety—Doxorubicin—ovarian cancer	0.000115	0.000736	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.000115	0.000734	CcSEcCtD
Haloperidol—Anorexia—Epirubicin—ovarian cancer	0.000114	0.00073	CcSEcCtD
Haloperidol—Dry mouth—Doxorubicin—ovarian cancer	0.000113	0.000723	CcSEcCtD
Haloperidol—Vomiting—Docetaxel—ovarian cancer	0.000113	0.000722	CcSEcCtD
Haloperidol—Rash—Docetaxel—ovarian cancer	0.000112	0.000716	CcSEcCtD
Haloperidol—Hypotension—Epirubicin—ovarian cancer	0.000112	0.000715	CcSEcCtD
Haloperidol—Dermatitis—Docetaxel—ovarian cancer	0.000112	0.000715	CcSEcCtD
Haloperidol—Confusional state—Doxorubicin—ovarian cancer	0.000112	0.000714	CcSEcCtD
Haloperidol—Headache—Docetaxel—ovarian cancer	0.000111	0.000711	CcSEcCtD
Haloperidol—Oedema—Doxorubicin—ovarian cancer	0.000111	0.000708	CcSEcCtD
Haloperidol—Anaphylactic shock—Doxorubicin—ovarian cancer	0.000111	0.000708	CcSEcCtD
Haloperidol—Nervous system disorder—Doxorubicin—ovarian cancer	0.000109	0.000695	CcSEcCtD
Haloperidol—Thrombocytopenia—Doxorubicin—ovarian cancer	0.000109	0.000694	CcSEcCtD
Haloperidol—Insomnia—Epirubicin—ovarian cancer	0.000108	0.000692	CcSEcCtD
Haloperidol—Tachycardia—Doxorubicin—ovarian cancer	0.000108	0.000691	CcSEcCtD
Haloperidol—Skin disorder—Doxorubicin—ovarian cancer	0.000108	0.000688	CcSEcCtD
Haloperidol—Hyperhidrosis—Doxorubicin—ovarian cancer	0.000107	0.000685	CcSEcCtD
Haloperidol—Dyspnoea—Epirubicin—ovarian cancer	0.000107	0.000683	CcSEcCtD
Haloperidol—Somnolence—Epirubicin—ovarian cancer	0.000107	0.000681	CcSEcCtD
Haloperidol—Anorexia—Doxorubicin—ovarian cancer	0.000106	0.000675	CcSEcCtD
Haloperidol—Nausea—Docetaxel—ovarian cancer	0.000106	0.000674	CcSEcCtD
Haloperidol—Dyspepsia—Epirubicin—ovarian cancer	0.000105	0.000674	CcSEcCtD
Haloperidol—Decreased appetite—Epirubicin—ovarian cancer	0.000104	0.000666	CcSEcCtD
Haloperidol—Hypotension—Doxorubicin—ovarian cancer	0.000104	0.000662	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000103	0.000661	CcSEcCtD
Haloperidol—Constipation—Epirubicin—ovarian cancer	0.000102	0.000655	CcSEcCtD
Haloperidol—Insomnia—Doxorubicin—ovarian cancer	0.0001	0.000641	CcSEcCtD
Haloperidol—Dyspnoea—Doxorubicin—ovarian cancer	9.89e-05	0.000632	CcSEcCtD
Haloperidol—Feeling abnormal—Epirubicin—ovarian cancer	9.88e-05	0.000631	CcSEcCtD
Haloperidol—Somnolence—Doxorubicin—ovarian cancer	9.86e-05	0.00063	CcSEcCtD
Haloperidol—Dyspepsia—Doxorubicin—ovarian cancer	9.76e-05	0.000624	CcSEcCtD
Haloperidol—Decreased appetite—Doxorubicin—ovarian cancer	9.64e-05	0.000616	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Doxorubicin—ovarian cancer	9.57e-05	0.000612	CcSEcCtD
Haloperidol—Urticaria—Epirubicin—ovarian cancer	9.52e-05	0.000608	CcSEcCtD
Haloperidol—Constipation—Doxorubicin—ovarian cancer	9.48e-05	0.000606	CcSEcCtD
Haloperidol—Body temperature increased—Epirubicin—ovarian cancer	9.47e-05	0.000605	CcSEcCtD
Haloperidol—Feeling abnormal—Doxorubicin—ovarian cancer	9.14e-05	0.000584	CcSEcCtD
Haloperidol—Hypersensitivity—Epirubicin—ovarian cancer	8.83e-05	0.000564	CcSEcCtD
Haloperidol—Urticaria—Doxorubicin—ovarian cancer	8.81e-05	0.000563	CcSEcCtD
Haloperidol—Body temperature increased—Doxorubicin—ovarian cancer	8.77e-05	0.00056	CcSEcCtD
Haloperidol—Pruritus—Epirubicin—ovarian cancer	8.48e-05	0.000542	CcSEcCtD
Haloperidol—Diarrhoea—Epirubicin—ovarian cancer	8.2e-05	0.000524	CcSEcCtD
Haloperidol—Hypersensitivity—Doxorubicin—ovarian cancer	8.17e-05	0.000522	CcSEcCtD
Haloperidol—Dizziness—Epirubicin—ovarian cancer	7.93e-05	0.000506	CcSEcCtD
Haloperidol—Pruritus—Doxorubicin—ovarian cancer	7.85e-05	0.000501	CcSEcCtD
Haloperidol—Vomiting—Epirubicin—ovarian cancer	7.62e-05	0.000487	CcSEcCtD
Haloperidol—Diarrhoea—Doxorubicin—ovarian cancer	7.59e-05	0.000485	CcSEcCtD
Haloperidol—Rash—Epirubicin—ovarian cancer	7.56e-05	0.000483	CcSEcCtD
Haloperidol—Dermatitis—Epirubicin—ovarian cancer	7.55e-05	0.000482	CcSEcCtD
Haloperidol—Headache—Epirubicin—ovarian cancer	7.51e-05	0.00048	CcSEcCtD
Haloperidol—Dizziness—Doxorubicin—ovarian cancer	7.33e-05	0.000468	CcSEcCtD
Haloperidol—Nausea—Epirubicin—ovarian cancer	7.12e-05	0.000455	CcSEcCtD
Haloperidol—Vomiting—Doxorubicin—ovarian cancer	7.05e-05	0.00045	CcSEcCtD
Haloperidol—Rash—Doxorubicin—ovarian cancer	6.99e-05	0.000447	CcSEcCtD
Haloperidol—Dermatitis—Doxorubicin—ovarian cancer	6.99e-05	0.000446	CcSEcCtD
Haloperidol—Headache—Doxorubicin—ovarian cancer	6.95e-05	0.000444	CcSEcCtD
Haloperidol—Nausea—Doxorubicin—ovarian cancer	6.59e-05	0.000421	CcSEcCtD
Haloperidol—HRH1—Signaling by GPCR—MAPK1—ovarian cancer	5.11e-06	8.82e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—EGFR—ovarian cancer	5.11e-06	8.81e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—VEGFA—ovarian cancer	5.1e-06	8.81e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—CTNNB1—ovarian cancer	5.07e-06	8.75e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—STAT3—ovarian cancer	5.05e-06	8.72e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—NRAS—ovarian cancer	5.04e-06	8.7e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PPP2R1A—ovarian cancer	5.04e-06	8.7e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—MMP9—ovarian cancer	5.03e-06	8.69e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—VEGFA—ovarian cancer	5.02e-06	8.67e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—PIK3CD—ovarian cancer	5.02e-06	8.66e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	5.02e-06	8.66e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—PTEN—ovarian cancer	5.01e-06	8.64e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—STAT3—ovarian cancer	4.97e-06	8.59e-05	CbGpPWpGaD
Haloperidol—DRD2—GPCR downstream signaling—PIK3CA—ovarian cancer	4.97e-06	8.58e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—MMP9—ovarian cancer	4.97e-06	8.58e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—NRAS—ovarian cancer	4.96e-06	8.56e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—PTEN—ovarian cancer	4.94e-06	8.53e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—PIK3CD—ovarian cancer	4.94e-06	8.52e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—MAPK3—ovarian cancer	4.93e-06	8.51e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—PIK3CD—ovarian cancer	4.93e-06	8.51e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—PIK3CD—ovarian cancer	4.92e-06	8.5e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—KRAS—ovarian cancer	4.91e-06	8.48e-05	CbGpPWpGaD
Haloperidol—HTR2A—GPCR downstream signaling—PIK3CA—ovarian cancer	4.89e-06	8.44e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling by GPCR—AKT1—ovarian cancer	4.88e-06	8.43e-05	CbGpPWpGaD
Haloperidol—HRH1—GPCR downstream signaling—PIK3CA—ovarian cancer	4.88e-06	8.42e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—KRAS—ovarian cancer	4.83e-06	8.34e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—MAPK3—ovarian cancer	4.83e-06	8.34e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—KRAS—ovarian cancer	4.82e-06	8.33e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling by GPCR—AKT1—ovarian cancer	4.82e-06	8.32e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—FASN—ovarian cancer	4.82e-06	8.31e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—MYC—ovarian cancer	4.8e-06	8.28e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—VEGFA—ovarian cancer	4.79e-06	8.28e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—CAV1—ovarian cancer	4.75e-06	8.21e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—MAPK3—ovarian cancer	4.75e-06	8.2e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—STAT3—ovarian cancer	4.75e-06	8.2e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—SLC5A5—ovarian cancer	4.74e-06	8.18e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—NRAS—ovarian cancer	4.74e-06	8.18e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—MYC—ovarian cancer	4.7e-06	8.11e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—MAPK1—ovarian cancer	4.69e-06	8.1e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—EGFR—ovarian cancer	4.69e-06	8.1e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—ABCB1—ovarian cancer	4.68e-06	8.08e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—PIK3CD—ovarian cancer	4.65e-06	8.03e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—CAV1—ovarian cancer	4.64e-06	8.01e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—MYC—ovarian cancer	4.62e-06	7.98e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—TYMS—ovarian cancer	4.6e-06	7.93e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—MAPK1—ovarian cancer	4.59e-06	7.93e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—EGFR—ovarian cancer	4.59e-06	7.93e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—SLC2A1—ovarian cancer	4.57e-06	7.9e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	4.54e-06	7.84e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—MAPK3—ovarian cancer	4.54e-06	7.83e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—VEGFA—ovarian cancer	4.52e-06	7.81e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—MAPK1—ovarian cancer	4.52e-06	7.8e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—EGFR—ovarian cancer	4.52e-06	7.8e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—PIK3CA—ovarian cancer	4.51e-06	7.79e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—STAT3—ovarian cancer	4.48e-06	7.73e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—NRAS—ovarian cancer	4.47e-06	7.71e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—VEGFA—ovarian cancer	4.46e-06	7.7e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—PIK3CA—ovarian cancer	4.44e-06	7.67e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—ERBB2—ovarian cancer	4.43e-06	7.65e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—PIK3CA—ovarian cancer	4.43e-06	7.65e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—KRAS—ovarian cancer	4.43e-06	7.65e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—STAT3—ovarian cancer	4.42e-06	7.63e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—MYC—ovarian cancer	4.41e-06	7.62e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—NRAS—ovarian cancer	4.41e-06	7.61e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—CYP1B1—ovarian cancer	4.39e-06	7.57e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—MTOR—ovarian cancer	4.37e-06	7.55e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—PIK3CB—ovarian cancer	4.37e-06	7.55e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—CAV1—ovarian cancer	4.37e-06	7.55e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—ERBB2—ovarian cancer	4.36e-06	7.53e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—ERBB2—ovarian cancer	4.35e-06	7.51e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—KRAS—ovarian cancer	4.34e-06	7.49e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—CAV1—ovarian cancer	4.33e-06	7.48e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—PIK3CG—ovarian cancer	4.33e-06	7.47e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—MAPK1—ovarian cancer	4.32e-06	7.45e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—EGFR—ovarian cancer	4.31e-06	7.45e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—MTOR—ovarian cancer	4.3e-06	7.43e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—PIK3CB—ovarian cancer	4.3e-06	7.43e-05	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—PIK3CA—ovarian cancer	4.3e-06	7.43e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—MTOR—ovarian cancer	4.29e-06	7.41e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—PIK3CB—ovarian cancer	4.29e-06	7.41e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—PIK3CB—ovarian cancer	4.29e-06	7.41e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—MAPK3—ovarian cancer	4.28e-06	7.38e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—KRAS—ovarian cancer	4.27e-06	7.37e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—PIK3CG—ovarian cancer	4.23e-06	7.29e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—MAPK3—ovarian cancer	4.22e-06	7.29e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CXCL8—ovarian cancer	4.2e-06	7.26e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—HRAS—ovarian cancer	4.18e-06	7.21e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—MYC—ovarian cancer	4.16e-06	7.18e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	4.14e-06	7.15e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CXCL8—ovarian cancer	4.14e-06	7.14e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CXCL8—ovarian cancer	4.13e-06	7.12e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—HRAS—ovarian cancer	4.11e-06	7.09e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CDKN1B—ovarian cancer	4.1e-06	7.09e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—MYC—ovarian cancer	4.1e-06	7.09e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—HRAS—ovarian cancer	4.1e-06	7.08e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—KRAS—ovarian cancer	4.08e-06	7.04e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—PIK3CA—ovarian cancer	4.07e-06	7.03e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—MAPK1—ovarian cancer	4.07e-06	7.03e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—EGFR—ovarian cancer	4.07e-06	7.02e-05	CbGpPWpGaD
Haloperidol—DRD2—GPCR downstream signaling—AKT1—ovarian cancer	4.06e-06	7.01e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—PIK3CB—ovarian cancer	4.05e-06	7e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CDKN1B—ovarian cancer	4.04e-06	6.97e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CDKN1B—ovarian cancer	4.03e-06	6.96e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CASP3—ovarian cancer	4.02e-06	6.94e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—IL2—ovarian cancer	4.02e-06	6.93e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—MAPK1—ovarian cancer	4.02e-06	6.93e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—EGFR—ovarian cancer	4.01e-06	6.93e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—IL6—ovarian cancer	4e-06	6.9e-05	CbGpPWpGaD
Haloperidol—HTR2A—GPCR downstream signaling—AKT1—ovarian cancer	3.99e-06	6.9e-05	CbGpPWpGaD
Haloperidol—HRH1—GPCR downstream signaling—AKT1—ovarian cancer	3.99e-06	6.88e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—PIK3CA—ovarian cancer	3.99e-06	6.88e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—PIK3CG—ovarian cancer	3.98e-06	6.87e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CASP3—ovarian cancer	3.96e-06	6.83e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—IL2—ovarian cancer	3.95e-06	6.82e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CASP3—ovarian cancer	3.95e-06	6.82e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PIK3CG—ovarian cancer	3.95e-06	6.81e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—IL2—ovarian cancer	3.94e-06	6.81e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—TP53—ovarian cancer	3.94e-06	6.8e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—IL6—ovarian cancer	3.93e-06	6.79e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—IL6—ovarian cancer	3.92e-06	6.77e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—PIK3CA—ovarian cancer	3.92e-06	6.77e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CCND1—ovarian cancer	3.92e-06	6.76e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	3.89e-06	6.71e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CTNNB1—ovarian cancer	3.88e-06	6.69e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—TP53—ovarian cancer	3.86e-06	6.66e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CCND1—ovarian cancer	3.85e-06	6.65e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CCND1—ovarian cancer	3.84e-06	6.64e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—KRAS—ovarian cancer	3.84e-06	6.64e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CTNNB1—ovarian cancer	3.82e-06	6.59e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CTNNB1—ovarian cancer	3.81e-06	6.57e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—PIK3CD—ovarian cancer	3.81e-06	6.57e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—MMP9—ovarian cancer	3.8e-06	6.56e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—TP53—ovarian cancer	3.79e-06	6.55e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—KRAS—ovarian cancer	3.79e-06	6.55e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—PTEN—ovarian cancer	3.78e-06	6.52e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—HRAS—ovarian cancer	3.77e-06	6.5e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—PIK3CA—ovarian cancer	3.74e-06	6.46e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—MMP9—ovarian cancer	3.74e-06	6.46e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—MMP9—ovarian cancer	3.73e-06	6.44e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—PTEN—ovarian cancer	3.72e-06	6.42e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—PIK3CD—ovarian cancer	3.71e-06	6.41e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—PTEN—ovarian cancer	3.71e-06	6.41e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—PTEN—ovarian cancer	3.71e-06	6.4e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—CAV1—ovarian cancer	3.7e-06	6.39e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—HRAS—ovarian cancer	3.69e-06	6.37e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—AKT1—ovarian cancer	3.69e-06	6.37e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—HRAS—ovarian cancer	3.63e-06	6.27e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—AKT1—ovarian cancer	3.63e-06	6.26e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—TP53—ovarian cancer	3.62e-06	6.25e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—AKT1—ovarian cancer	3.62e-06	6.25e-05	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—PIK3CA—ovarian cancer	3.62e-06	6.25e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—ABCB1—ovarian cancer	3.61e-06	6.23e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—IL6—ovarian cancer	3.6e-06	6.22e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—TYMS—ovarian cancer	3.55e-06	6.12e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	3.54e-06	6.11e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—PIK3CA—ovarian cancer	3.53e-06	6.1e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—IL6—ovarian cancer	3.53e-06	6.09e-05	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—AKT1—ovarian cancer	3.51e-06	6.07e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—PTEN—ovarian cancer	3.5e-06	6.05e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—PIK3CD—ovarian cancer	3.5e-06	6.04e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—PIK3CA—ovarian cancer	3.48e-06	6.02e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—IL6—ovarian cancer	3.47e-06	6e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PIK3CD—ovarian cancer	3.47e-06	5.99e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—HRAS—ovarian cancer	3.46e-06	5.98e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—TP53—ovarian cancer	3.42e-06	5.9e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—VEGFA—ovarian cancer	3.41e-06	5.89e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—STAT3—ovarian cancer	3.38e-06	5.84e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PIK3CG—ovarian cancer	3.37e-06	5.82e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—NRAS—ovarian cancer	3.37e-06	5.82e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—TP53—ovarian cancer	3.37e-06	5.82e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—VEGFA—ovarian cancer	3.36e-06	5.8e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—VEGFA—ovarian cancer	3.35e-06	5.79e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—AKT1—ovarian cancer	3.33e-06	5.74e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—STAT3—ovarian cancer	3.33e-06	5.74e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—STAT3—ovarian cancer	3.32e-06	5.73e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—NRAS—ovarian cancer	3.32e-06	5.73e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—PIK3CB—ovarian cancer	3.32e-06	5.73e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—IL6—ovarian cancer	3.32e-06	5.72e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—NRAS—ovarian cancer	3.31e-06	5.72e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—HRAS—ovarian cancer	3.27e-06	5.64e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—AKT1—ovarian cancer	3.26e-06	5.62e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—PIK3CB—ovarian cancer	3.24e-06	5.59e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—MAPK3—ovarian cancer	3.23e-06	5.57e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—HRAS—ovarian cancer	3.22e-06	5.57e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—AKT1—ovarian cancer	3.2e-06	5.53e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—MAPK3—ovarian cancer	3.18e-06	5.49e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—MAPK3—ovarian cancer	3.17e-06	5.47e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—MYC—ovarian cancer	3.14e-06	5.42e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—IL6—ovarian cancer	3.13e-06	5.4e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—MYC—ovarian cancer	3.09e-06	5.34e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—IL6—ovarian cancer	3.09e-06	5.33e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—MYC—ovarian cancer	3.08e-06	5.32e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—MAPK1—ovarian cancer	3.07e-06	5.3e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—EGFR—ovarian cancer	3.07e-06	5.3e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—AKT1—ovarian cancer	3.06e-06	5.28e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—PIK3CB—ovarian cancer	3.05e-06	5.27e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PIK3CB—ovarian cancer	3.02e-06	5.22e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—MAPK1—ovarian cancer	3.02e-06	5.22e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—EGFR—ovarian cancer	3.02e-06	5.22e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—MAPK1—ovarian cancer	3.02e-06	5.21e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—EGFR—ovarian cancer	3.02e-06	5.21e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PIK3CD—ovarian cancer	2.97e-06	5.12e-05	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—AKT1—ovarian cancer	2.96e-06	5.1e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—KRAS—ovarian cancer	2.9e-06	5.01e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—AKT1—ovarian cancer	2.88e-06	4.98e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—PTEN—ovarian cancer	2.87e-06	4.95e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—CAV1—ovarian cancer	2.86e-06	4.93e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—KRAS—ovarian cancer	2.86e-06	4.93e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—KRAS—ovarian cancer	2.85e-06	4.92e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—AKT1—ovarian cancer	2.85e-06	4.91e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—PTEN—ovarian cancer	2.8e-06	4.83e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—PIK3CA—ovarian cancer	2.67e-06	4.6e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—PTEN—ovarian cancer	2.64e-06	4.55e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—PIK3CA—ovarian cancer	2.62e-06	4.53e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—PIK3CA—ovarian cancer	2.62e-06	4.52e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—PIK3CA—ovarian cancer	2.62e-06	4.52e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PTEN—ovarian cancer	2.61e-06	4.51e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PIK3CG—ovarian cancer	2.6e-06	4.49e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PIK3CB—ovarian cancer	2.58e-06	4.46e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—TP53—ovarian cancer	2.58e-06	4.45e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—TP53—ovarian cancer	2.54e-06	4.38e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—TP53—ovarian cancer	2.53e-06	4.37e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—PIK3CA—ovarian cancer	2.47e-06	4.27e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—HRAS—ovarian cancer	2.47e-06	4.26e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—HRAS—ovarian cancer	2.43e-06	4.19e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—HRAS—ovarian cancer	2.42e-06	4.18e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—IL6—ovarian cancer	2.36e-06	4.08e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—IL6—ovarian cancer	2.32e-06	4.01e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—IL6—ovarian cancer	2.32e-06	4e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PIK3CD—ovarian cancer	2.29e-06	3.95e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PTEN—ovarian cancer	2.23e-06	3.86e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—AKT1—ovarian cancer	2.18e-06	3.76e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—AKT1—ovarian cancer	2.14e-06	3.7e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—AKT1—ovarian cancer	2.14e-06	3.69e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—AKT1—ovarian cancer	2.14e-06	3.69e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—PIK3CA—ovarian cancer	2.02e-06	3.49e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—AKT1—ovarian cancer	2.02e-06	3.49e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PIK3CB—ovarian cancer	1.99e-06	3.44e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—PIK3CA—ovarian cancer	1.97e-06	3.41e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—PIK3CA—ovarian cancer	1.86e-06	3.21e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PIK3CA—ovarian cancer	1.84e-06	3.18e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PTEN—ovarian cancer	1.72e-06	2.98e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—AKT1—ovarian cancer	1.65e-06	2.85e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—AKT1—ovarian cancer	1.61e-06	2.78e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PIK3CA—ovarian cancer	1.58e-06	2.72e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—AKT1—ovarian cancer	1.52e-06	2.62e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—AKT1—ovarian cancer	1.51e-06	2.6e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—AKT1—ovarian cancer	1.29e-06	2.22e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PIK3CA—ovarian cancer	1.22e-06	2.1e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—AKT1—ovarian cancer	9.93e-07	1.71e-05	CbGpPWpGaD
